Minerva Neurosciences
Waltham, Massachusetts, United States · Biopharma, Biotechnology, Health Care · 8 employees
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development of therapies to treat patients suffering from neuropsychiatric diseases. The company's lead drug, roluperidone, is being developed to address the negative symptoms of schizophrenia, which represent a significant unmet medical need. With a commitment to advancing innovative treatments, Minerva aims to imp
Funding history
- Funding Round — $200.0M — Oct 2025
- Series seed — $1.0M — Mar 2016
Recent signals
- Apr 02, 2026: Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO
- Oct 21, 2025: Raised $200.0M
- Oct 21, 2025: SEC 8-K (1.01): On October 21, 2025, Minerva Neurosciences, Inc. entered into a Securities Purchase Agreement with certain accredited investors, agreeing to issue 80,000 shares of Series A Convertible Preferred Stock at a purchase price of $1,000 per share as part of a private placement. Additionally, the agreement includes tranche A and tranche B warrants, giving investors rights to acquire additional shares of Series A Preferred Stock. This agreement signifies a strategic move by Minerva to raise capital, which may foster future growth and operational initiatives. The key parties involved are Minerva Neurosciences, Inc. and the accredited investors participating in the private placement.
- Mar 18, 2016: Raised $1.0M in Series seed
See plans & pricing → Track Minerva Neurosciences’s funding, hiring, and signals — with verified contacts — on Fundz.